Date: 2013-02-18
Type of information:
Compound: antibodies against an undisclosed number of U3 Pharma targets
Company: AbCheck (Czech Republic) U3 Pharma - a Daiichi Sankyo company (Germany - Japan)
Therapeutic area: Undisclosed
Type agreement: R&D
Action mechanism:
Disease:
Details: AbCheck, a Czech multi antibody discovery platforms company, has entered into a research collaboration with U3 Pharma, the antibody targeted cancer drug development affiliate of Daiichi Sankyo Co. Under the agreement AbCheck will use its AbSieve discovery platform, which combines the Company’s proprietary phage and yeast display technologies, to deliver antibodies against an undisclosed number of U3 Pharma targets. U3 Pharma, which has full rights to any antibodies selected, will pay AbCheck discovery fees and milestone payments. Other financial and deal terms are not disclosed.
AbCheck s.r.o. focuses on the discovery and/or optimization of human antibodies for partner companies. AbSieve, the combined phage and yeast display platforms, is used to develop antibodies in all antibody formats including full length IgGs as well as customer specific and novel antibody formats. AbAccel, a proprietary algorithm for affinity maturation and optimization, is combined with Phage or Yeast Display and addresses affinity maturation, developability and stability optimization of antibodies in just one step.
U3 Pharma GmbH, based in Martinsried near Munich, Germany, is a leader in targeted cancer drug development. Established in July 2001, the company has produced a pipeline of novel targeted therapeutics based on the ground-breaking discoveries made by its founder - Professor Axel Ullrich. Since May 2008, U3 Pharma has been an affiliate of Daiichi Sankyo Co.
Financial terms: U3 Pharma, which has full rights to any antibodies selected, will pay AbCheck discovery fees and milestone payments. Other financial and deal terms are not disclosed.
Latest news:
